$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

$abvc Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022072317 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$589.0K	$42.27K	$99.00K
YoY Change	65.54%	-57.3%	-14.32%
Cost Of Revenue	$265.4K	$10.74K	$390.00
YoY Change	5114.34%	2654.1%	-95.48%
Gross Profit	$323.6K	$31.53K	$98.61K
YoY Change	-7.74%	-68.03%	-7.78%
Gross Profit Margin	54.94%	74.59%	99.61%
Selling, General & Admin	$1.961M	$3.216M	$1.806M
YoY Change	-82.26%	78.11%	43.06%
% of Gross Profit	605.97%	10200.92%	1831.19%
Research & Development	$1.496M	$305.5K	$263.4K
YoY Change	49.01%	15.97%	95.85%
% of Gross Profit	462.26%	968.93%	267.13%
Depreciation & Amortization	$6.440K	$6.462K	$2.860K
YoY Change	97.55%	125.94%	-67.24%
% of Gross Profit	1.99%	20.5%	2.9%
Operating Expenses	$3.457M	$3.747M	$2.069M
YoY Change	-71.33%	81.11%	48.15%
Operating Profit	-$3.133M	-$3.716M	-$1.971M
YoY Change	-73.24%	88.57%	52.78%
Interest Expense	-$358.8K	$126.5K	-$127.1K
YoY Change	1202.72%	-199.55%	-85.61%
% of Operating Profit
Other Income/Expense, Net	$63.86K	-$56.46K	$135.8K
YoY Change	-87.78%	-141.59%	2240.52%
Pretax Income	-$3.538M	-$3.772M	-$1.962M
YoY Change	-68.44%	92.28%	-9.83%
Income Tax	$962.9K	$4.222K	-$75.67K
% Of Pretax Income
Net Earnings	-$4.864M	-$3.705M	-$1.806M
YoY Change	-62.12%	105.09%	-2.14%
Net Earnings / Revenue	-825.81%	-8764.97%	-1824.74%
Basic Earnings Per Share		-$0.11	-$0.07
Diluted Earnings Per Share	-$0.15	-$0.11	-$67.20K
COMMON SHARES
Basic Shares Outstanding	32.63M shares	32.63M shares	26.88M shares
Diluted Shares Outstanding		32.57M shares	26.88M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$161.1K	$1.401M	$3.827M
YoY Change	-97.29%	-63.39%	2719.93%
Cash & Equivalents	$85.27K	$1.324M	$3.716M
Short-Term Investments	$75.80K	$77.58K	$111.3K
Other Short-Term Assets	$1.457M	$933.8K	$2.190M
YoY Change	-25.29%	-57.36%	1775.16%
Inventory		$20.49K	$60.01K
Prepaid Expenses
Receivables	$98.33K	$47.68K	$473.2K
Other Receivables	$513.8K	$500.0K	$561.1K
Total Short-Term Assets	$2.987M	$2.903M	$7.111M
YoY Change	-68.96%	-59.17%	503.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$574.0K	$566.8K	$2.082M
YoY Change	9.15%	-72.78%	-11.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$842.1K	$816.2K	$1.007M
YoY Change	-9.72%	-18.91%	-15.56%
Other Assets	$4.291M	$4.951M	$2.155M
YoY Change	275.62%	129.71%	19.05%
Total Long-Term Assets	$6.868M	$7.577M	$5.244M
YoY Change	68.63%	44.5%	-2.01%
TOTAL ASSETS
Total Short-Term Assets	$2.987M	$2.903M	$7.111M
Total Long-Term Assets	$6.868M	$7.577M	$5.244M
Total Assets	$9.855M	$10.48M	$12.35M
YoY Change	-28.05%	-15.17%	89.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable			$16.50K
YoY Change			-28.48%
Accrued Expenses	$2.910M	$1.201M	$1.476M
YoY Change	123.68%	-18.59%	-51.49%
Deferred Revenue	$10.99K
YoY Change
Short-Term Debt	$1.894M	$1.866M	$1.637M
YoY Change	15.47%	13.99%	-14.98%
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$5.820M	$3.894M	$3.439M
YoY Change	57.61%	13.24%	-43.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$104.2K
YoY Change		-100.0%	-16.26%
Other Long-Term Liabilities	$799.8K	$893.1K	$1.222M
YoY Change	-29.56%	-26.92%	-21.22%
Total Long-Term Liabilities	$799.8K	$893.1K	$1.326M
YoY Change	-29.56%	-32.66%	-20.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.820M	$3.894M	$3.439M
Total Long-Term Liabilities	$799.8K	$893.1K	$1.326M
Total Liabilities	$6.619M	$4.787M	$3.761M
YoY Change	37.11%	27.3%	-46.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$54.90M	-$50.04M
YoY Change	42.68%
Common Stock	$32.86K	$32.63K
YoY Change	13.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$9.100M	$9.100M
YoY Change	0.0%
Treasury Stock Shares
Shareholders Equity	$3.099M	$5.919M	$8.594M
YoY Change
Total Liabilities & Shareholders Equity	$9.855M	$10.48M	$12.35M
YoY Change	-28.05%	-15.17%	89.22%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$4.864M	-$3.705M	-$1.806M
YoY Change	-62.12%	105.09%	-2.14%
Depreciation, Depletion And Amortization	$6.440K	$6.462K	$2.860K
YoY Change	97.55%	125.94%	-67.24%
Cash From Operating Activities	-$461.1K	-$513.7K	-$2.684M
YoY Change	-77.58%	-80.86%	716.44%
INVESTING ACTIVITIES
Capital Expenditures	$90.00	-$4.350K	-$17.50K
YoY Change		-75.14%
Acquisitions
YoY Change
Other Investing Activities	-$83.20K	-$1.519M	-$324.9K
YoY Change	100.05%	367.46%	-11.19%
Cash From Investing Activities	-$83.28K	-$1.523M	-$342.4K
YoY Change	100.24%	344.83%	-6.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-253.5K	603.5K	5.817M
YoY Change	-105.96%	-89.63%	1211.19%
NET CHANGE
Cash From Operating Activities	-461.1K	-513.7K	-2.684M
Cash From Investing Activities	-83.28K	-1.523M	-342.4K
Cash From Financing Activities	-253.5K	603.5K	5.817M
Net Change In Cash	-797.9K	-1.433M	2.791M
YoY Change	-137.02%	-151.36%	-1211.97%
FREE CASH FLOW
Cash From Operating Activities	-$461.1K	-$513.7K	-$2.684M
Capital Expenditures	$90.00	-$4.350K	-$17.50K
Free Cash Flow	-$461.2K	-$509.4K	-$2.667M
YoY Change	-77.57%	-80.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40700
	dei	Entity Registrant Name EntityRegistrantName	ABVC BioPharma, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0014658
	dei	Entity Address Address Line1 EntityAddressAddressLine1	44370 Old Warm Springs Blvd.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
	dei	Entity Address Country EntityAddressCountry	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
	dei	City Area Code CityAreaCode	(510)
	dei	Local Phone Number LocalPhoneNumber	668-0881
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ABVC
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32632329	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1323543	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5828548	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	646604	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	736667	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	47680	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	280692	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	145399	usd
CY2022Q3	abvc	Prepayment For Longterm Investments PrepaymentForLongtermInvestments	500000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	20489	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	25975	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	77583	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	108147	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	287181	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	528354	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	2903080	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	7653782	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	566751	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525881	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1243930	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1471899	usd
CY2022Q3	us-gaap	Long Term Investments LongTermInvestments	816160	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	932755	usd
CY2022Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1013159	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	981912	usd
CY2022Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	103218	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	119309	usd
CY2022Q3	us-gaap	Security Deposit SecurityDeposit	57656	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	41157	usd
CY2022Q3	abvc	Prepayment For Longterm Investments Noncurrent PrepaymentForLongtermInvestmentsNoncurrent	2586658	usd
CY2021Q4	abvc	Prepayment For Longterm Investments Noncurrent PrepaymentForLongtermInvestmentsNoncurrent	1153155	usd
CY2022Q3	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	1190255	usd
CY2021Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	818183	usd
CY2022Q3	us-gaap	Assets Assets	10480567	usd
CY2021Q4	us-gaap	Assets Assets	13698033	usd
CY2022Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	1866250	usd
CY2021Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	1640000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1201497	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1300803	usd
CY2022Q3	abvc	Advance From Customers AdvanceFromCustomers	10985	usd
CY2021Q4	abvc	Advance From Customers AdvanceFromCustomers	10985	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	363752	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	347100	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	451826	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	393424	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3894310	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3692312	usd
CY2022Q3	us-gaap	Security Deposit Liability SecurityDepositLiability	12880	usd
CY2021Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	10580	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	880178	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1124799	usd
CY2022Q3	us-gaap	Liabilities Liabilities	4787368	usd
CY2021Q4	us-gaap	Liabilities Liabilities	4827691	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32632329	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32632329	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28926322	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28926322	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	32632	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	28926	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	66493649	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	58113667	usd
CY2022Q3	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	1580180	usd
CY2021Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	2257400	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50040501	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38481200	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-113081	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-539660	usd
CY2022Q3	us-gaap	Treasury Stock Value TreasuryStockValue	9100000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	9100000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	5918681	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8843653	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-225482	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	26689	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5693199	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8870342	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10480567	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13698033	usd
CY2022Q3	us-gaap	Revenues Revenues	42269	usd
CY2021Q3	us-gaap	Revenues Revenues	98999	usd
	us-gaap	Revenues Revenues	380789	usd
	us-gaap	Revenues Revenues	393590	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	10741	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	393	usd
	us-gaap	Cost Of Revenue CostOfRevenue	21004	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2284	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	31528	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	98606	usd
	us-gaap	Gross Profit GrossProfit	359785	usd
	us-gaap	Gross Profit GrossProfit	391306	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3216146	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1579996	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6000055	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3979283	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	305483	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	263424	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1197669	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	743617	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	225740	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	225740	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5143483	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	927220	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3747369	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	2069160	usd
	us-gaap	Operating Expenses OperatingExpenses	12341207	usd
	us-gaap	Operating Expenses OperatingExpenses	5650120	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3715841	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1970554	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11981422	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5258814	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	48164	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	9333	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	127354	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	72584	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	126536	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	38677	usd
	us-gaap	Interest Expense InterestExpense	159507	usd
	us-gaap	Interest Expense InterestExpense	251577	usd
CY2022Q3	abvc	Rent Income RentIncome	21597	usd
CY2021Q3	abvc	Rent Income RentIncome	2624	usd
	abvc	Rent Income RentIncome	78523	usd
	abvc	Rent Income RentIncome	60822	usd
CY2021Q3	abvc	Operating Sublease Income Related Parties OperatingSubleaseIncomeRelatedParties	1200	usd
	abvc	Operating Sublease Income Related Parties OperatingSubleaseIncomeRelatedParties	3600	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-177	usd
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5999	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	17865	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-10806	usd
CY2021Q3	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-91765	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-193147	usd
CY2022Q3	us-gaap	Other Income OtherIncome	491	usd
CY2021Q3	us-gaap	Other Income OtherIncome	-404	usd
	us-gaap	Other Income OtherIncome	-59381	usd
	us-gaap	Other Income OtherIncome	-171	usd
CY2021Q3	us-gaap	Interest Income Securities Us Treasury And Other Us Government InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment	132331	usd
	us-gaap	Interest Income Securities Us Treasury And Other Us Government InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment	256731	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-56461	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8643	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4854	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-61964	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3772302	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1961911	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11976568	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5320778	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4222	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-75667	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-165096	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-186255	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3776524	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-1886244	usd
	us-gaap	Profit Loss ProfitLoss	-11811472	usd
	us-gaap	Profit Loss ProfitLoss	-5134523	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-71660	usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-79756	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-252171	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-227964	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3704864	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1806488	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11559301	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4906559	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-190019	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	16137	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-426579	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	416858	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3894883	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1790351	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11985880	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4489701	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.2
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32574551	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26882181	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31193397	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25035522	shares
	us-gaap	Profit Loss ProfitLoss	-11811472	usd
	us-gaap	Profit Loss ProfitLoss	-5134523	usd
	us-gaap	Depreciation Depreciation	17364	usd
	us-gaap	Depreciation Depreciation	8725	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5143483	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	927220	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-193147	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	256731	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	521955	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-30564	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-31247	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-187055	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	31909	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	171655	usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	243065	usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-647219	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	983707	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-422651	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-5486	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	59673	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6547	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-99306	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-338928	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1085	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	58402	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	178570	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6937322	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5073103	usd
	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	119603	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	110700	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17503	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	1518793	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	1104609	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1638396	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1232812	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3917425	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6875000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	850429	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	350000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	306836	usd
	abvc	Repayment Of Shortterm Loan RepaymentOfShorttermLoan	100000	usd
	abvc	Repayment Of Notes Payable RepaymentOfNotesPayable	107100	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	236498	usd
	abvc	Repayment Of Long Term Bank Loans RepaymentOfLongTermBankLoans	4396	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4267425	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5742737	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-286775	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11579	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4595068	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-551599	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6565215	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5001371	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1970147	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4449772	usd
	us-gaap	Interest Paid Net InterestPaidNet	161741	usd
	us-gaap	Interest Paid Net InterestPaidNet	327642	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1600	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2662067	usd
CY2021Q1	abvc	Stock Issued During Period Value Share Based Compensation Services StockIssuedDuringPeriodValueShareBasedCompensationServices	225740	usd
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-1195323	usd
CY2021Q1	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	36140	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1728624	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	250000	usd
CY2021Q2	abvc	Stock Issued During Period Value Share Based Compensation Services StockIssuedDuringPeriodValueShareBasedCompensationServices	225740	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-2052956	usd
CY2021Q2	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	364581	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	515989	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6024571	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	2693548	usd
CY2021Q3	abvc	Stock Issued During Period Value Share Based Compensation Services StockIssuedDuringPeriodValueShareBasedCompensationServices	225740	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-1886244	usd
CY2021Q3	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	16137	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7589741	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8870342	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4466263	usd
CY2022Q1	abvc	Stock Issued During Period Value Share Based Compensation Services StockIssuedDuringPeriodValueShareBasedCompensationServices	225740	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-6087615	usd
CY2022Q1	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-113339	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7361391	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3663925	usd
CY2022Q2	abvc	Stock Issued During Period Value Share Based Compensation Services StockIssuedDuringPeriodValueShareBasedCompensationServices	225740	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1947333	usd
CY2022Q2	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-123221	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9180502	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	253500	usd
CY2022Q3	abvc	Stock Issued During Period Value Share Based Compensation Services StockIssuedDuringPeriodValueShareBasedCompensationServices	225740	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3776524	usd
CY2022Q3	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-190019	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5693199	usd
CY2016Q1	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	2536-for-1, into an aggregate of 166,273,921 (52,936,583 pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company.
CY2017Q3	abvc	Percentage Of Common Shares Issued And Outstanding PercentageOfCommonSharesIssuedAndOutstanding	0.73	pure
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-11811472	usd
	abvc	Working Capital WorkingCapital	991230	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6937322	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Reclassifications of Prior Year Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year unaudited consolidated balance sheet and unaudited consolidated cash flow statement amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Fiscal Period FiscalPeriod	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fiscal Year</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2016Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	360000000	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1323543	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5828548	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	646604	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	736667	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We perform ongoing credit evaluation of our customers and requires no collateral. An allowance for doubtful accounts is provided based on a review of the collectability of accounts receivable. We determine the amount of allowance for doubtful accounts by examining its historical collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit losses may differ from our estimates<span style="font-family: Times New Roman, Times, Serif">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	9	usd
	abvc	Labour Pension Fund Percentage LabourPensionFundPercentage	0.06	pure
	abvc	Percentage Of Monthly Contributions PercentageOfMonthlyContributions	0.06	pure
CY2022Q3	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	3302	usd
CY2021Q3	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2906	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	9948	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	8268	usd
CY2022Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2021Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	9	usd
CY2021Q3	abvc	Stock Based Compensation For Nonemployees StockBasedCompensationForNonemployees	225740	usd
CY2022Q3	abvc	Stock Based Compensation For Nonemployees StockBasedCompensationForNonemployees	225740	usd
	abvc	Stock Based Compensation For Nonemployees StockBasedCompensationForNonemployees	5143483	usd
	abvc	Stock Based Compensation For Nonemployees StockBasedCompensationForNonemployees	927220	usd
	abvc	Beneficial Conversion Feature BeneficialConversionFeature	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Beneficial Conversion Feature</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	abvc	Defined Benefit Plan Funded Percentages DefinedBenefitPlanFundedPercentages	0.50	pure
	abvc	Milestone Payments Royalty Percentage MilestonePaymentsRoyaltyPercentage	0.12	pure
CY2018Q4	abvc	Co Dev Agreement Description CoDevAgreementDescription	On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	93901	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	96725	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	62537	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	84620	usd
CY2022Q3	abvc	Allowance For Inventory Valuation And Obsolescence Loss AllowanceForInventoryValuationAndObsolescenceLoss	135949	usd
CY2021Q4	abvc	Allowance For Inventory Valuation And Obsolescence Loss AllowanceForInventoryValuationAndObsolescenceLoss	155370	usd
CY2022Q3	us-gaap	Inventory Gross InventoryGross	20489	usd
CY2021Q4	us-gaap	Inventory Gross InventoryGross	25975	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3855029	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3840352	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3288278	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3314471	usd
CY2022Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	566751	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	525881	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6462	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2856	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17364	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8725	usd
	abvc	Schedule Of Ownership Percentages Of Investee Table Text Blocks ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ownership percentage</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Accounting</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name of related party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">treatments</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Genepharm Biotech Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.70</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.70</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioHopeKing Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">BioFirst Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15.99</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15.99</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Equity Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rgene Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31.62</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31.62</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Equity Method</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"> </p>
CY2022Q3	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	816160	usd
CY2021Q4	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	932755	usd
CY2022Q3	us-gaap	Equity Method Investments EquityMethodInvestments	816160	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	932755	usd
	abvc	Purchase Additional Shares PurchaseAdditionalShares	317000	shares
CY2022Q3	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	599130	usd
CY2021Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	684720	usd
CY2021	abvc	Total Amount TotalAmount	465000	usd
CY2021Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.065	pure
	abvc	Total Amount TotalAmount	1365000	usd
CY2022Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.065	pure
	us-gaap	Federal Home Loan Bank Advances Activity For Year Average Balance Of Agreements Outstanding FederalHomeLoanBankAdvancesActivityForYearAverageBalanceOfAgreementsOutstanding	1830000	usd
CY2021	us-gaap	Federal Home Loan Bank Advances Activity For Year Average Balance Of Agreements Outstanding FederalHomeLoanBankAdvancesActivityForYearAverageBalanceOfAgreementsOutstanding	465000	usd
CY2022Q3	us-gaap	Financing Receivable Accrued Interest After Allowance For Credit Loss FinancingReceivableAccruedInterestAfterAllowanceForCreditLoss	81404	usd
CY2021Q4	us-gaap	Financing Receivable Accrued Interest After Allowance For Credit Loss FinancingReceivableAccruedInterestAfterAllowanceForCreditLoss	2325	usd
CY2022Q3	abvc	Capital Leases Contingent Rental Payment Due CapitalLeasesContingentRentalPaymentDue	75824	usd
CY2021Q4	abvc	Capital Leases Contingent Rental Payment Due CapitalLeasesContingentRentalPaymentDue	1110	usd
	abvc	Aggregate Amount AggregateAmount	2586658	usd
CY2021	abvc	Aggregate Amount AggregateAmount	1153155	usd
	abvc	Share Of Equity Method Investee Losses ShareOfEquityMethodInvesteeLosses	-193147	usd
CY2018Q2	us-gaap	Stock Issued1 StockIssued1	5000000	usd
CY2018Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2
CY2018Q2	abvc	Shares Offering Price Percentage SharesOfferingPricePercentage	0.80	pure
CY2018Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	500000	usd
CY2020Q1	us-gaap	Investment Interest Rate InvestmentInterestRate	0.20	pure
CY2020Q2	abvc	Aggregate Principal And Accrued Interest Expense AggregatePrincipalAndAccruedInterestExpense	354722	usd
CY2020Q2	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	192784	shares
CY2018Q2	us-gaap	Stock Issued1 StockIssued1	5000000	usd
CY2018Q3	us-gaap	Stock Issued1 StockIssued1	5000000	usd
CY2019Q3	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.70	pure
CY2019Q3	abvc	Public Equity Offering Exceed Amount PublicEquityOfferingExceedAmount	10000000	usd
CY2020	abvc	Shares Issued1 SharesIssued1	111112	shares
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.25
CY2021Q3	abvc	Convertible Promissory Note ConvertiblePromissoryNote	2500000	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1111112	shares
CY2022Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	1866250	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1640000	usd
CY2021Q3	abvc	Principal Amount principalAmount	7500000	twd
CY2021Q3	abvc	Principal Amount principalAmount	236250	usd
CY2021Q3	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2022Q3	abvc	Principal Amount principalAmount	7500000	twd
CY2022Q3	abvc	Principal Amount principalAmount	236250	usd
CY2022Q3	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2017Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2019-07-18
CY2022Q1	abvc	Principal Amount principalAmount	20000000	twd
CY2022Q1	abvc	Principal Amount principalAmount	630000	usd
CY2022Q3	abvc	Principal Amount principalAmount	20000000	twd
CY2022Q3	abvc	Principal Amount principalAmount	630000	usd
CY2019Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000000	usd
CY2020Q2	abvc	Received Loan Amount ReceivedLoanAmount	350000	usd
CY2020Q4	abvc	Received Loan Amount ReceivedLoanAmount	350000	usd
CY2021Q4	abvc	Principal Amount principalAmount	650000	usd
CY2020Q2	abvc	Loan From Paycheck Protection Program LoanFromPaycheckProtectionProgram	124400	usd
CY2020Q2	abvc	Forgiven Amount Percentage Used For Payroll ForgivenAmountPercentageUsedForPayroll	0.60	pure
CY2021Q1	abvc	Loan From Paycheck Protection Program LoanFromPaycheckProtectionProgram	132331	usd
CY2021Q1	abvc	Forgiven Amount Percentage Used For Payroll ForgivenAmountPercentageUsedForPayroll	0.60	pure
CY2021Q1	abvc	Promissory Note Description PromissoryNoteDescription	The loan was granted pursuant to a promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. No collateral or personal guarantees are required.
CY2021Q1	abvc	Loan From Paycheck Protection Programs LoanFromPaycheckProtectionPrograms	104167	usd
CY2021Q1	abvc	Forgiven Amount Percentage Used For Payroll ForgivenAmountPercentageUsedForPayroll	0.60	pure
CY2021Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.01	pure
CY2019Q1	abvc	Unsecured Loan Agreements Description UnsecuredLoanAgreementsDescription	In January, 2019, BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $94,500, for working capital purpose.
CY2022Q3	us-gaap	Other Notes Payable OtherNotesPayable	0	usd
CY2021Q4	us-gaap	Other Notes Payable OtherNotesPayable	0	usd
CY2022Q3	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
CY2021Q3	us-gaap	Interest Expense Other InterestExpenseOther	2142	usd
	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
	us-gaap	Interest Expense Other InterestExpenseOther	8568	usd
CY2020Q1	us-gaap	Unsecured Debt UnsecuredDebt	100000	usd
CY2020Q3	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.015	pure
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	0	usd
CY2021	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	0	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	145399	usd
CY2022Q3	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	500000	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	16670	usd
CY2022Q3	us-gaap	Due From Other Related Parties Noncurrent DueFromOtherRelatedPartiesNoncurrent	1190255	usd
CY2021Q4	us-gaap	Due From Other Related Parties Noncurrent DueFromOtherRelatedPartiesNoncurrent	818183	usd
CY2022Q3	abvc	Aggregate Principal Amount AggregatePrincipalAmount	500000	usd
CY2021Q4	abvc	Aggregate Principal Amount AggregatePrincipalAmount	0	usd
CY2022Q3	us-gaap	Government Assistance Amount Cumulative Noncurrent GovernmentAssistanceAmountCumulativeNoncurrent	1480	usd
	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.12	pure
	us-gaap	Assets Average Outstanding AssetsAverageOutstanding	501480	usd
CY2021	us-gaap	Assets Average Outstanding AssetsAverageOutstanding	33520	usd
CY2022Q2	abvc	Convertible Loan ConvertibleLoan	500000	usd
CY2022Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	1000000	usd
CY2022Q2	abvc	Bears Interest BearsInterest	0.05	pure
CY2022Q2	abvc	Working Capital Percentage WorkingCapitalPercentage	0.064	pure
	abvc	Conversion Price Description ConversionPriceDescription	The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.
CY2022Q3	us-gaap	Due From Affiliate Noncurrent DueFromAffiliateNoncurrent	0	usd
CY2021Q4	us-gaap	Due From Affiliate Noncurrent DueFromAffiliateNoncurrent	1889	usd
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-11-30
CY2022Q1	abvc	Loan Agreement Total Amount LoanAgreementTotalAmount	507000	usd
CY2022Q1	abvc	Interest Rate InterestRate	0.065	pure
CY2022Q3	us-gaap	Due From Employees Noncurrent DueFromEmployeesNoncurrent	0	usd
CY2021Q4	us-gaap	Due From Employees Noncurrent DueFromEmployeesNoncurrent	124972	usd
	abvc	Schedule Of Related Party Transactions Amount Due To Related Party ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">September 30,</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December 31,</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">BioFirst Corporation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,878</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,878</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">BioFirst (Australia)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">211,147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">132,443</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>AsiaGene</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,017</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>YuanGene</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,205</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">The Jiangs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,789</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Due to shareholders</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">146,790</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">168,131</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">451,826</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">393,424</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"> </p>
CY2022Q3	abvc	Due To Related Party Current And Noncurrent DueToRelatedPartyCurrentAndNoncurrent	451826	usd
CY2021Q4	abvc	Due To Related Party Current And Noncurrent DueToRelatedPartyCurrentAndNoncurrent	393424	usd
CY2022Q3	abvc	Accrued Interest AccruedInterest	40878	usd
CY2021Q4	abvc	Accrued Interest AccruedInterest	40878	usd
CY2018	us-gaap	Debt Instrument Interest Rate Terms DebtInstrumentInterestRateTerms	The advances bear interest rate of 12% per annum.
CY2022Q3	abvc	Outstanding Principal And Accrued Interest OutstandingPrincipalAndAccruedInterest	146790	usd
CY2021Q4	abvc	Outstanding Principal And Accrued Interest OutstandingPrincipalAndAccruedInterest	168131	usd
CY2022Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	5208	usd
CY2021Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	5679	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	15922	usd
	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-187055	usd
CY2022Q3	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	800	usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1600	usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	800	usd
CY2022Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	800	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1600	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	800	usd
CY2022Q3	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	3422	usd
CY2021Q3	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-75667	usd
	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-166696	usd
CY2022Q3	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	3422	usd
CY2021Q3	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-75667	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-166696	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-187055	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4222	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-75667	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-165096	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-186255	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	648716	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	741390	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	402245	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	283725	usd
	us-gaap	Investment Tax Credit InvestmentTaxCredit	610914	usd
CY2021	us-gaap	Investment Tax Credit InvestmentTaxCredit	698187	usd
CY2022Q3	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	1661875	usd
CY2021Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	1723302	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	648716	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	741390	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1013159	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	981912	usd
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	abvc	Common Stock Share Authorized CommonStockShareAuthorized	360000000	shares
CY2016Q2	abvc	Agreement Description AgreementDescription	On May 6, 2016, the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company’s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.
CY2016Q3	abvc	Agreement Description AgreementDescription	The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016.
CY2017Q1	abvc	Agreement Description AgreementDescription	In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company’s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company’s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit).
CY2019Q2	abvc	Financial Amendment Description FinancialAmendmentDescription	On May 3, 2019, the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (“FINRA”). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company’s common stock were exchanged for 17,693,625 shares of the Company’s Common Stock.
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	644972	shares
	us-gaap	Professional Fees ProfessionalFees	4514800	usd
CY2022Q2	abvc	Stock Subscription Receivable StockSubscriptionReceivable	1580180	usd
CY2021Q4	abvc	Stock Subscription Receivable StockSubscriptionReceivable	2257400	usd
CY2019Q3	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4872340	usd
CY2019Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	7
CY2019Q3	abvc	Debt Conversion Converted Instrument Amount DebtConversionConvertedInstrumentAmount	4872340	usd
CY2019Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	696051	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50000	shares
CY2021Q2	us-gaap	Share Price SharePrice	5
CY2020Q4	abvc	Warrant Issued WarrantIssued	200000	shares
CY2020Q4	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	2.25
CY2020Q4	abvc	Warrant Term WarrantTerm	P5Y
CY2020Q4	abvc	Issuance Of Common Stock IssuanceOfCommonStock	3384615	shares
CY2020	abvc	Aggregate Common Stock Shares AggregateCommonStockShares	915856	shares
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1111112	shares
CY2021Q3	abvc	Convertible Promissory Note Value ConvertiblePromissoryNoteValue	2500000	usd
CY2021Q3	abvc	Description Of Public Offering DescriptionOfPublicOffering	On August 5, 2021, the Company closed its public offering (the “Public Offering”) of 1,100,000 units (the “Units”), with each Unit consisting of one share of the Company’s common stock, one Series A warrant (the “Series A Warrants”) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the “Series B Warrants,” and together with the Series A Warrants, the “Public Warrants”) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the “SEC”) on April 8, 2021 (as amended, the “Original Registration Statement”), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the “S-1MEF,” together with the Original Registration Statement, the “Registration Statement”). The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000.
CY2021Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4244452	usd
CY2021Q4	abvc	Aggregate Common Stock Shares AggregateCommonStockShares	673605	shares
CY2021Q4	abvc	Consulting Agreement Desciption ConsultingAgreementDesciption	In November 2021, the Company entered into consulting agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted $1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant date. These shares have been issued during the year ended December 31, 2021. In January 2022, the Company agreed to pay the deferred service fees related to Public Offering amounted $4,296,763 by issuing 1,306,007 shares of unrestricted common shares, valued at $3.29 per share on the grant date. These shares have been issued in January 2022.
CY2022Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	75000	shares
CY2022Q1	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	169500	usd
CY2022Q1	us-gaap	Share Price SharePrice	2.26
CY2022Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	2000000	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4220000	usd
	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	556075	usd
	abvc	Warrants Term WarrantsTerm	P5Y
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	2000000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.45
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	545182	shares
CY2020Q4	abvc	Conversion Price ConversionPrice	2
CY2020Q4	abvc	Consulting Fees ConsultingFees	1090361	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	545182	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1280002	shares
CY2021Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0851	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.09
CY2022Q3	abvc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants	$0
	abvc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants	$0
	abvc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants	$0
CY2021Q3	abvc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants	$0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	761920	shares
CY2022Q2	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3704864	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1806488	usd
CY2022Q3	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	32574551
CY2021Q3	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	26882181
CY2022Q3	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	32574551
CY2021Q3	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	26882181
CY2022Q3	abvc	Loss Per Share Basic LossPerShareBasic	-0.11
CY2021Q3	abvc	Loss Per Share Basic LossPerShareBasic	-0.07
CY2022Q3	abvc	Loss Per Share Diluted LossPerShareDiluted	-0.11
CY2021Q3	abvc	Loss Per Share Diluted LossPerShareDiluted	-0.07
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11559301	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4906559	usd
	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	31193397
	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	25053522
	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	31193397
	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	25053522
	abvc	Loss Per Share Basic LossPerShareBasic	-0.37
	abvc	Loss Per Share Basic LossPerShareBasic	-0.2
	abvc	Loss Per Share Diluted LossPerShareDiluted	-0.37
	abvc	Loss Per Share Diluted LossPerShareDiluted	-0.2
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1243930	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1471899	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	363752	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	347100	usd
CY2022Q3	abvc	Operating Lease Liabilitienoncurrent OperatingLeaseLiabilitienoncurrent	880178	usd
CY2021Q4	abvc	Operating Lease Liabilitienoncurrent OperatingLeaseLiabilitienoncurrent	1124799	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	87367	usd
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	86280	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	261494	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	165127	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	261494	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	165127	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M14D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0152	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0139	pure
CY2022Q3	abvc	Operating Leases Future Minimum Payment Due Current OperatingLeasesFutureMinimumPaymentDueCurrent	91387	usd
CY2022Q3	abvc	Operating Leases Future Minimum Payment Due In Two Years OperatingLeasesFutureMinimumPaymentDueInTwoYears	371055	usd
CY2022Q3	abvc	Operating Leases Future Minimum Payment Due In Three Years OperatingLeasesFutureMinimumPaymentDueInThreeYears	386244	usd
CY2022Q3	abvc	Operating Leases Future Minimum Payment Due In Four Years OperatingLeasesFutureMinimumPaymentDueInFourYears	348525	usd
CY2022Q3	abvc	Operating Leases Future Minimum Payment Due There After OperatingLeasesFutureMinimumPaymentDueThereAfter	56915	usd
CY2022Q3	abvc	Operating Leases Future Minimum Payment Due OperatingLeasesFutureMinimumPaymentDue	1254126	usd
CY2022Q3	abvc	Interest Portion Of Minimum Lease Payments Sale Lease Back Transaction InterestPortionOfMinimumLeasePaymentsSaleLeaseBackTransaction	10196	usd
CY2022Q3	abvc	Present Value Of Future Minimum Lease Payment Sale Leaseback Transactions PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions	1243930	usd
CY2019Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	44341847	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	531147	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	188550	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	56075	usd
CY2019Q1	abvc	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets	485684	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	10440	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	1271896	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	56204	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	251335	usd
CY2019Q1	abvc	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability	-267256	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther	2880	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	577675	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	694221	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	43647626	usd
CY2019Q1	abvc	Percentage Of Goodwill PercentageOfGoodwill	1	pure
CY2019Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	43647626	usd
CY2022Q3	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent		usd
CY2022Q3	us-gaap	Goodwill Goodwill		usd
CY2021Q4	us-gaap	Goodwill Goodwill		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	abvc	Operating Sublease Income Related Parties OperatingSubleaseIncomeRelatedParties		usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss		usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss		usd
CY2022Q3	us-gaap	Interest Income Securities Us Treasury And Other Us Government InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment		usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	abvc	Share Of Equity Method Investee Losses ShareOfEquityMethodInvesteeLosses		usd
CY2022Q3	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26882181	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31193397	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32574551	shares
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes		usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease		usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	abvc	Repayment Of Long Term Bank Loans RepaymentOfLongTermBankLoans		usd
CY2021Q3	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	1.13	pure
CY2022Q3	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
CY2021Q3	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001173313

Files In Submission

Name	View Source	Status
0001213900-22-072317-index-headers.html	Edgar Link	pending
0001213900-22-072317-index.html	Edgar Link	pending
0001213900-22-072317.txt	Edgar Link	pending
0001213900-22-072317-xbrl.zip	Edgar Link	pending
abvc-20220930.xsd	Edgar Link	pending
f10q0922ex31-1_abvcbio.htm	Edgar Link	pending
f10q0922ex31-2_abvcbio.htm	Edgar Link	pending
f10q0922ex32-1_abvcbio.htm	Edgar Link	pending
f10q0922ex32-2_abvcbio.htm	Edgar Link	pending
f10q0922_abvcbio.htm	Edgar Link	pending
abvc-20220930_cal.xml	Edgar Link	unprocessable
abvc-20220930_def.xml	Edgar Link	unprocessable
abvc-20220930_lab.xml	Edgar Link	unprocessable
abvc-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0922_abvcbio_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

2022 Q4 Form 10-Q Financial Statement

#000121390022072317 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC ABVC BIOPHARMA, INC. Stock $abvc

2022 Q4 Form 10-Q Financial Statement

#000121390022072317 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc